Abstracts

NEAR-PERFECT ACCURACY OF A REAL-TIME URINE TENOFOVIR TEST COMPARED TO LAB-BASED ELISA

Therapeutic drug monitoring measures adherence to tenofovir (TFV)-based PrEP more accurately than self-report but has not been available at the point-of-care (POC) until now. We developed an ELISA using a highly-selective antibody to TFV in urine and previously validated it against spectrometry-based methods with high accuracy. We have now developed a lateral flow immunoassay (LFA) using…

RISKS OF METABOLIC SYNDROME, DIABETES, AND CARDIOVASCULAR DISEASE IN ADVANCE TRIAL

In the ADVANCE trial, more patients taking first-line TAF/FTC+DTG developed clinical obesity compared to TDF/FTC+DTG and TDF/FTC/EFV. Common associations with obesity include type 2 diabetes, cardiovascular disease (CVD), and metabolic syndrome. This analysis aimed to quantify these risks using standard risk algorithms. In ADVANCE, 1,053 treatment-naïve patients in South Africa (99% black, 59% female) were…

CYP2B6 GENOTYPE AND WEIGHT-GAIN DIFFERENCES BETWEEN DOLUTEGRAVIR AND EFAVIRENZ

Two African trials reported more weight gain with dolutegravir (DTG) than efavirenz (EFV), especially in women. EFV is toxic to mitochondria and is associated with lipoatrophy. We hypothesised that CYP2B6 metaboliser genotype, which predicts EFV exposure, would determine amount of weight gained and fat distribution in patients starting EFV-based ART. Participants enrolled in the EFV/TDF/FTC…

LOSARTAN TO REDUCE INFLAMMATION AND FIBROSIS ENDPOINTS IN HIV DISEASE (LIFE-HIV)

Persistent inflammation and incomplete immune recovery among persons with HIV are associated with increased disease risk. Angiotensin receptor blockers (ARB) have been shown to down-regulate inflammation and fibrosis, in part, via inhibition of NFkB and TGFb pathways, respectively.  We hypothesized that the ARB losartan would reduce inflammation, inhibit fibrosis, and concurrently improve immune recovery. Treatment effects…

AZITHROMYCIN FOR TREATMENT OF HIV-RELATED CHRONIC LUNG DISEASE IN AFRICAN CHILDREN

HIV-related chronic lung disease (HCLD) in children and adolescents is associated with substantial morbidity, despite antiretroviral therapy (ART). HCLD may be a consequence of repeated respiratory tract infections and/or dysregulated immune activation. Macrolides have anti-inflammatory and antimicrobial properties, and we hypothesized that azithromycin (AZM) would improve lung function and morbidity through preventing respiratory tract infections…